CSI Market
Sign In | Register

Panbela Therapeutics Inc (PBLA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PBLA Annual Cash Flow →
A period-by-period view of cash flow from Panbela Therapeutics Inc to Sep 30 2023 helps clarify how Sep 30 2024's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
9 Months 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Operating Activities
Income-21.44
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Intangible Assets-0.78
Share-based Compensation0.10
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Contributed Services-
Imputed Interest On Related Party Notes Payable-
Noncash Interest Expense0.52
Payments To Acquire Deposits Investing Activities-
Research And Development In Process-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Income Taxes Receivable-0.14
Increase (Decrease) in Accounts Payable0.80
Increase (Decrease) in Accrued Liabilities4.09
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.17
Other Working Capital4.52
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-12.49
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.78
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Note Receivable Related Party-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.78
Financing Activities
Short-term debt Net2.20
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-1.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Issuance Of Lease Payable-
Proceeds From Deposits For Possible Future Stock Sales-
Proceeds From Issuance Or Sale Of Equity Net-
Proceeds From Issuance Of Common Stock Net8.08
Payments For Fractional Shares-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities9.28
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-11.72
Total Cash Flow-2.44
4 historic quarters locked

Sign in to unlock the full Panbela Therapeutics Inc cash flow history.

Sign In Create Free Account

About Panbela Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-24-035315

Figures are derived from filed reports and may be restated. Historical data is subject to revision.